Adenocarcinoma Research Reveals Breakthrough in Nivolumab Therapy

Strategic Insights -

Research conducted by a team of scientists at Gifu University Hospital in Japan has shown that early induction of nivolumab monotherapy as a third-line or later treatment in patients with gastric adenocarcinoma can be an effective strategy. The study, which involved 53 patients, demonstrated a progression-free survival rate of 35.7% at 6 months and a median progression-free survival of 4.0 months. The researchers also found that baseline T-cell invigoration rate was associated with both response rate and prognosis, while baseline cell-free DNA was associated with prognosis but not with response rate.

Key Takeaways:

  • The VOYAGER trial demonstrated the efficacy of nivolumab monotherapy as a third-line or later treatment in patients with gastric adenocarcinoma, with a progression-free survival rate of 35.7% at 6 months.
  • The study found that baseline T-cell invigoration rate was associated with both response rate and prognosis, suggesting that T-cell activity may be a key predictor of treatment success.
  • The ratio of baseline T-cell invigoration to baseline cell-free DNA was strongly associated with response rate, indicating that this biomarker may have clinical utility in predicting treatment outcomes.
  • The researchers concluded that early induction of nivolumab as a later-line regimen is an alternative strategy for patients with gastric adenocarcinoma, and identified clinically available predictors for PD-1 blockade therapy.
  • The study highlights the importance of biomarker analysis in predicting treatment outcomes and identifying potential treatment strategies for patients with gastric adenocarcinoma.
  • The results of the VOYAGER trial suggest that nivolumab monotherapy may be a viable treatment option for patients with gastric adenocarcinoma, particularly those with low tumor burden and minimal T-cell exhaustion.
  • The study also highlights the potential of cell-free DNA as a tumor burden surrogate and a prognostic biomarker.

Statistics:

  • 53 patients were enrolled in the VOYAGER trial
  • 35.7% of patients achieved a progression-free survival rate at 6 months
  • Median progression-free survival was 4.0 months (95% CI 2.3-5.7)
  • Median overall survival was 10.9 months (95% CI 9.9-16.0)
  • T-cell invigoration rate was associated with a response rate of 44.1%
  • Cell-free DNA was associated with a prognosis but not with response rate
  • The ratio of baseline T-cell invigoration to baseline cell-free DNA was strongly associated with response rate (P=0.007)

Sources:

  • ESMO Gastrointestinal Oncology, 2025,8():100148
  • https://doi-org.sdpl.idm.oclc.org/10.1016/j.esmogo.2025.100148
  • A. Makiyama, Cancer Center, Gifu University Hospital, Gifu, Japan
  • Q. Hu, T. Nagasaka, H. Katsuya, A. Nishioka, I. Yasufuku, T. Kashiwada, Y. Shinohara, S. Otsu, M. Shimokawa, H. Saeki, H. Baba, E. Oki